Journal Watch · Drug Discovery Today · 2026

Targeting S1P signaling for drug development.

Here, we discuss the modulators and their preliminary structure-activity relationships in terms of the generation, transportation, and degradation of S1P.

Liu Y, Song Y, Wang Y et al.Drug Discovery Today3 min readPharma relevance 85/100

DOI: 10.1016/j.drudis.2026.104674PMID: 42000126Study type: clinical study

TL;DR

Here, we discuss the modulators and their preliminary structure-activity relationships in terms of the generation, transportation, and degradation of S1P.

Key findings

  • Five agonists of its receptor have been approved for the treatment of multiple sclerosis, and an inhibitor targeting its production is currently undergoing clinical trials for cancer therapy.
  • Here, we discuss the modulators and their preliminary structure-activity relationships in terms of the generation, transportation, and degradation of S1P.

What they did

Sphingosine-1-phosphate (S1P), a downstream metabolite of the sphingolipid pathway, exerts diverse biological functions, is implicated in a wide spectrum of diseases, and has been shown to have central roles in regulating cell proliferation, migration, and immune cell trafficking.

Full abstract (original)

Abstract: Sphingosine-1-phosphate (S1P), a downstream metabolite of the sphingolipid pathway, exerts diverse biological functions, is implicated in a wide spectrum of diseases, and has been shown to have central roles in regulating cell proliferation, migration, and immune cell trafficking. Five agonists of its receptor have been approved for the treatment of multiple sclerosis, and an inhibitor targeting its production is currently undergoing clinical trials for cancer therapy. Here, we discuss the modulators and their preliminary structure-activity relationships in terms of the generation, transportation, and degradation of S1P.

Abstract © the authors / Drug Discovery Today (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.drudis.2026.104674 · PubMed 42000126.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Drug Discovery Today study find?

Here, we discuss the modulators and their preliminary structure-activity relationships in terms of the generation, transportation, and degradation of S1P.

What type of study is this?

It is a clinical study, published in Drug Discovery Today in 2026. Sphingosine-1-phosphate (S1P), a downstream metabolite of the sphingolipid pathway, exerts diverse biological functions, is implicated in a wide spectrum of diseases, and has been shown to have central roles in regulating cell proliferation, migration, and immune cell trafficking.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.drudis.2026.104674. PubMed ID: 42000126. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Liu Y, Song Y, Wang Y et al.. Targeting S1P signaling for drug development.. Drug Discovery Today (2026). DOI: 10.1016/j.drudis.2026.104674.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/targeting-s1p-signaling-for-drug-development-104674/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides